[Newsmp] The Ministry of Food and Drug Safety (MFDS) revealed that the number of patent registrations during the first quarter fell to two-thirds of the level compared to the same period last year.
According to the MFDS information platform (https://nedrug.mfds.go.kr/), the number of patents registered during the first quarter dropped to 43, down by 25 from 68 in the same period last year.
Janssen Korea stood out by registering seven patents on its own.
Janssen registered three patents for its urothelial cancer therapy Balversa (erdafitinib), three patents for its multiple sclerosis therapy Ponvory (ponesimod), and one patent for its blood cancer therapy Imbruvica (ibrutinib).
JW Pharmaceutical and Lilly were tied in second place, registering four patents each, following Janssen.
JW Pharmaceutical secured three patents for its anemia in chronic kidney disease treatment Enaroy (enarodustat), and one patent for its hemophilia treatment Hemlibra (emicizumab). Lilly obtained four patents for Trulicity alone.
Moreover, HK inno.N, Daewoong Pharmaceutical, Dong-A ST, Yuhan Corporation, Novartis Korea, Roche Korea, AstraZeneca Korea, and Korea United Pharm. have each listed two patents.
Two patents each have been registered by HK inno.N for its antiemetic medicine Akynzeo (fosnetupitant and palonosetron), and by Daewoong Pharmaceutical for its SGLT-2 inhibitor Envlo (enavogliflozin).
Dong-A ST has listed one patent each for its osteoporosis treatment, Teribone (teriparatide), and its toenail fungus infection treatment, Jublia (efinaconazole), while Yuhan Corporation has secured one patent each for its cholesterol-lowering drug, Fenowell (fenofibrate), and its neuropathic pain treatment, Yuhan Pregabalin SR Tab. (pregabalin).
Novartis Korea has secured two patents for its treatment of psoriasis and autoimmune diseases using Cosentyx (secukinumab), while Roche Korea has obtained one patent each for its Alecensa (alectinib) drug ALK inhibitor that helps treat ALK+ metastatic NSCLC and its Tecentriq (atezolizumab) drug, an immune checkpoint inhibitor targeting PD-L1.
AstraZeneca Korea has obtained patents for Ultomiris (ravulizumab), its treatment for paroxysmal nocturnal hemoglobinuria (PNH), while Korea United Pharm. has secured two patents for Atmeg Combigel, a medication that combines atorvastatin and omega-3 acids.
Other companies, GSK, Daewon Pharmaceutical, Mitsubishi Tanabe Pharma Korea, Sanofi-Aventis, Jeil Pharmaceutical, Chong Kun Dang Pharmaceutical, Taejoon Pharma, Takeda Korea, Servier Korea, AbbVie Korea, Pfizer Korea, and Hanmi Pharmaceutical have each registered a single patent.
GSK has been granted a patent for Jemperli (dostarlimab), an anti-PD-1 immune checkpoint inhibitor, while Daewon Pharmaceutical has obtained a patent for Pelubi S (pelubiprofen), an arthritis treatment. Mitsubishi Tanabe Pharma has secured a patent for Novastan Hi (argatroban), an anticoagulant, and Sanofi has obtained a patent for Libtayo (cemiplimab), an anti-PD-1 immune checkpoint inhibitor.
In addition, Jeil Pharmaceutical registered a patent for its urinary incontinence treatment Beova (vibegron), while Chong Kun Dang Pharmaceutical secured a patent for its vitamin supplement Benfobell (benfotiamine and others). Taejoon Pharmaceutical registered a patent for its bowel cleansing Cleanviewal (ascorbic acid and others), and Takeda registered a patent for its inflammatory bowel disorder treatment Kynteles (vedolizumab).
Servier Korea has registered a patent for Oncaspar (pegaspargase), a treatment for acute lymphoblastic leukemia. AbbVie Korea has registered a patent for Ozurdex (dexamethasone), a drug used to treat diabetic macular edema. Pfizer Korea has registered a patent for their COVID-19 vaccine, Comirnaty Inj. (tozinameran), while Hanmi Pharmaceutical has registered a patent for their diabetes medication, Linaglo Duo (linagliptin and metformin).
